ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

4:00PM-4:50PM: Abstract Number: 1471

Healthy Lifestyle and Risk of Rheumatoid Arthritis in Women: A Prospective Cohort Study

Epidemiology & Public Health II: Risk Factors & Outcomes (1467–1471)

4:00PM-4:50PM: Abstract Number: 1450

Integrative Analysis of DNA Methylation and Gene Expression in Monocytes from Primary Antiphospholipid Syndrome Patients Identifies a Gene Expression Signature Associated with Their Atherothrombotic Phenotype

Antiphospholipid Syndrome (1447–1451)

4:00PM-4:50PM: Abstract Number: 1482

Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis

Osteoarthritis I: Clinical Trials (1482–1486)

4:00PM-4:50PM: Abstract Number: 1485

LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis

Osteoarthritis I: Clinical Trials (1482–1486)

4:00PM-4:50PM: Abstract Number: 1486

Long-term Efficacy and Safety of Intra-articular Sprifermin in Patients with Knee Osteoarthritis: Results from the 5-Year Forward Study

Osteoarthritis I: Clinical Trials (1482–1486)

4:00PM-4:50PM: Abstract Number: 1451

Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE

Antiphospholipid Syndrome (1447–1451)

4:00PM-4:50PM: Abstract Number: 1470

Machine Learning-Based Prediction of Knee Replacement in Persons with and Without Radiographic Osteoarthritis Using Clinical and Imaging Features of Osteoarthritis: The Multicenter Osteoarthritis Study

Epidemiology & Public Health II: Risk Factors & Outcomes (1467–1471)

4:00PM-4:50PM: Abstract Number: 1496

Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome

Pediatric Rheumatology – Clinical I: Treatment of JIA (1492–1496)

4:00PM-4:50PM: Abstract Number: 1494

Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts

Pediatric Rheumatology – Clinical I: Treatment of JIA (1492–1496)

4:00PM-4:50PM: Abstract Number: 1515

Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort

SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516)

4:00PM-4:50PM: Abstract Number: 1513

Role of Platelet C4d in Thrombosis and Lupus Nephritis

SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516)

4:00PM-4:50PM: Abstract Number: 1448

Single-cell RNA Sequencing of Livedo Reticularis Skin Reveals Endothelial Pathology in Antiphospholipid Syndrome

Antiphospholipid Syndrome (1447–1451)

4:00PM-4:50PM: Abstract Number: 1468

The Association of Walking Speed from Short- and Standard-Distance Tests with Mortality Risk Among Adults with Radiographic Knee Osteoarthritis: Data from Johnston County Osteoarthritis Project, Osteoarthritis Initiative and Multicenter Osteoarthritis Study

Epidemiology & Public Health II: Risk Factors & Outcomes (1467–1471)

4:00PM-4:50PM: Abstract Number: 1492

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes

Pediatric Rheumatology – Clinical I: Treatment of JIA (1492–1496)

4:00PM-4:50PM: Abstract Number: 1514

The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study

SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].